On September 16, 2021, DiQi Pharma's independently developed modified new drug, Risperidone Microspheres for Injection (4W), received clinical trial approval from the U.S. Food and Drug Administration (FDA). This product had already obtained clinical trial approval from the National Medical Products Administration (NMPA) on April 14, 2021.

Autumn's dry weather makes it a peak season for fire incidents. On September 9, the Safety Production Committee of DiQi Pharma organized its annual fire drill, inviting professionals from the Yue'an Fire Prevention Management Center to conduct on-site training and safety exercises at the company.

Today's professionals face increasingly fast-paced work and life rhythms, bearing ever-growing pressures. Excessive and sustained stress can severely impact employees' physical and mental well-being. To guide employees in learning to manage stress effectively, the trade union, with strong support from the Party branch, meticulously organized a session. Integrating this with the company's “Saturday Training School” program, they invited Ms. Sun Yonghong, Director of the Psychology Department at Guangzhou Cadre Health Management Center, through the Huangpu District Talent Center and Talent Group, to deliver a lecture to all employees. This initiative received enthusiastic responses from all departments across the company.

DiQi Pharma developed a lower-cost formulation and manufacturing process tailored to the product's characteristics, establishing proprietary dissolution conditions. This successfully achieved consistency between in vitro dissolution and in vivo bioequivalence, enabling the bioequivalence study to pass on the first attempt!

Recently, the Party branch of Guangzhou DiQi Pharmaceuticals Co., Ltd. and the Party branch of China International Capital Corporation Wealth Management's Guangzhou Tiyudong Road Business Department conducted a joint Party-building partnership activity. At the meeting, both parties signed a “Party-building Partnership Agreement” and engaged in exchanges on the study of Party history.

To further deepen university-enterprise collaboration and support the development of South China University of Technology's biomedical engineering program, DiQi Pharma and the School of Biomedical Science and Engineering have initiated multi-dimensional, close cooperation through models such as the Guangdong Provincial Joint Graduate Training Demonstration Base, industry-academia-research projects, and university-enterprise face-to-face initiatives.

On the morning of September 27, 2020, the plaque presentation ceremony for the Guangdong Provincial Joint Graduate Training Demonstration Base, jointly established by South China University of Technology and Guangzhou DiQi Pharmaceuticals Co., Ltd, was held at DiQi Pharma.

People often place all their hopes for rescuing victims of accidents or critical illnesses solely on hospitals and doctors, while lacking on-site first aid knowledge. This frequently causes patients facing life-threatening situations to lose precious minutes—sometimes as many as ten or more—of critical rescue time. To promote first-aid knowledge, enhance safety awareness, and strengthen employees' ability to respond to emergencies and perform self-rescue and mutual aid, our company conducted emergency evacuation drills on August 26 and first-aid training sessions with fire equipment instruction on August 27.